| Outcome Measures: |
Primary: Changes in HbA1c between active treatment groups and placebo at Week 12, Change in HbA1c from Baseline to Week 12, 12 Weeks | Secondary: HbA1c of < 7.0% at Week 12, Proportion of Subjects with HbA1c of \< 7.0% at Week 12, 12 Weeks|HbA1c of < 6.5% at Week 12, Proportion of Subjects with HbA1c of \< 6.5% at Week 12, 12 Weeks|Changes in Fasting Plasma Glucose (FPG) from Baseline to Week 12 between active treatment groups and placebo, Changes in FPG from Baseline to Week 12, 12 Weeks|Changes in fasting insulin, insulin sensitivities (HOMA IR), Changes in fasting insulin, insulin sensitivities (HOMA IR) from Baseline to Week 12, 12 Weeks|Changes in lipid profile (low density lipoprotein cholesterol [LDL-C], high density lipoprotein cholesterol [HDL-C], triglycerides), Changes in lipid profile (low density lipoprotein cholesterol \[LDL-C\], high density lipoprotein cholesterol \[HDL-C\], triglycerides) from Baseline to Week 12, 12 Weeks|Changes in Body Weight, Changes in Body Weight from Baseline to Week 12, 12 Weeks
|
